
Opinion|Videos|March 19, 2025
Treatment Decision-Making for Metastatic NSCLC With a ROS1 Alteration
Panelists discuss treatment decision-making for metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, focusing on targeted therapies and personalized treatment strategies.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
IMNN-001 Plus Chemo Cuts MRD Rate in Frontline Ovarian Cancer
5






























